INNATE PHARMA : THIRD QUARTER 2015 REPORT
05 Novembre 2015 - 7:35AM
Third quarter 2015 report
- Cash, cash equivalents and financial instruments amounting
to €270 million ;
- US$5 million milestone payment received from Bristol-Myers
Squibb for the initiation of a new Phase II trial in
hemato-oncology ;
- Programs on track.
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 -
IPH) today announced its revenues and cash position for the first
nine months of 2015.
Cash, cash equivalents and financial instruments
of the Company amounted to €269.6 million at September 30,
2015. At the same date, its financial liabilities amounted to €3.9
million (lease-financing of its premises).
Revenues for the first nine months of 2015
amounted to €13.1 million (€1.0 million for the same period in
2014).
|
Nine months ending September 30 |
Three months ending September 30 |
In thousands of euros |
2015 |
2014 |
2015 |
2014 |
Revenues
from collaboration and licensing agreements |
13,088 |
972 |
9,996 |
(55) |
Revenue |
13,088 |
972 |
9,996 |
(55) |
This revenue results from Innate Pharma's
collaboration and licensing agreement with Bristol-Myers Squibb and
co-development and commercialization agreement with
AstraZeneca:
- €5.5 million from the agreement with Bristol-Myers Squibb
including a €4.4 million milestone payment as well as €0.7 million
from the recognition over the period of the upfront payment
received in July 2011;
- €7.6 million resulting from the agreement with AstraZeneca,
corresponding to the recognition over the period of the initial
payment received in April 2015.
Revenue for the first nine months of 2014 mainly
resulted from the recognition over the period of the upfront
payment received in 2011 from Bristol-Myers Squibb (€0.6
million).
Business update: During the period, clinical
and research discovery activities moved forward as anticipated.
Regarding Innate's three most advanced programs:
- Lirilumab: a first patient was dosed in the Phase II
trial of lirilumab in combination with rituximab in patients with
relapsed/refractory or high-risk untreated Chronic Lymphocytic
Leukemia, triggering a milestone payment from Bristol-Myers
Squibb;
- IPH2201: a first patient was treated in the Phase I/II
trial in ovarian cancer and the Phase I/II trial in combination
with ibrutinib in patients with relapsed or refractory chronic
lymphocytic leukemia started;
- IPH4102: the rationale of the program and the Phase I
design were presented at the cutaneous lymphoma task force meeting
of the EORTC as well as during a KOL event organized in New-York.
The enrolment of the first patient is expected in the coming
weeks.
About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical
company discovering and developing first-in-class therapeutic
antibodies for the treatment of cancer and inflammatory
diseases.
The Company has three clinical-stage programs,
including two checkpoint inhibitors in immuno-oncology, a new
therapeutic field that is changing cancer treatment by enhancing
the capability of the body's own immune cells to recognize and kill
cancer cells.
Its innovative approach has translated into
major alliances with leaders in the biopharmaceutical industry such
as Novo Nordisk A/S, Bristol-Myers Squibb and AstraZeneca.
Listed on Euronext-Paris, Innate Pharma is based
in Marseille, France, and had 112 employees at September 30,
2015.
Learn more about Innate Pharma at
www.innate-pharma.com.
Practical Information about Innate Pharma
shares:
ISIN
code Ticker code |
FR0010331421 IPH |
Disclaimer:
This press release contains certain
forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. For a discussion of risks and
uncertainties which could cause the company's actual results,
financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to
the Risk Factors ("Facteurs de Risque") section of the Document de
Reference prospectus filed with the AMF, which is available on the
AMF website or on Innate Pharma's website.
This press release and the information contained
herein do not constitute an offer to sell or a solicitation of an
offer to buy or subscribe to shares in Innate Pharma in any
country.
For additional information, please
contact:
Innate Pharma |
ATCG
Press |
Laure-Hélène Mercier Director,
Investor Relations |
Marie
Puvieux (France) Mob: +33 (0)6 10 54 36 72 Jean-Medhi Grangeon
(ROW) |
Tel.: +33 (0)4 30 30 30 87 |
Mob: +33
(0)6 62 22 00 24 |
investors@innate-pharma.com |
presse@atcg-partners.com |
PR in English http://hugin.info/155662/R/1964250/716917.pdf
HUG#1964250
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024